TFN Reader Grapevinde: There’s something about Viral Genetics, Inc. (VRAL)
Today's Financial News - Posted August 25, 2009
Recent activity surrounding biotech penny stock Viral Genetics, Inc. (OTC:VRAL) indicates this company could be ready for a boost
by J. Christoph Amberger
Baltimore, MD — TFN: TFN eNews reader Cliff X. filed the following with us this afternoon:
“Viral Genetics, Inc. (OTC:VRAL) is a small company that develops and commercializes a series of proteins based primarily on thymus nuclear protein (TNP). These relate to combatting infectious diseases, such as HIV/AIDS, other autoimmune conditions and immunological deficiency.
“Rumor has it that they are planning something big - heard about them filing with the FDA re: investigatory new drug filing within the month.
“Right now, it’s just speculation, but apparently others may know more than me, as the stock started flying today around mid-afternoon. I was lucky enough to get into it at $0.495. Maybe your other members would be interested.”
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • NBRI • Nov 4, 2024 9:00 AM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM